Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Jerome Lewis Avorn, M.D.

Co-Author

This page shows the publications co-authored by Jerome Avorn and Aaron Kesselheim.
Connection Strength

28.211
  1. Determinants of Market Exclusivity for Prescription Drugs in the United States. JAMA Intern Med. 2017 11 01; 177(11):1658-1664.
    View in: PubMed
    Score: 0.765
  2. FDA Approval of Eteplirsen for Muscular Dystrophy-Reply. JAMA. 2017 04 11; 317(14):1481-1482.
    View in: PubMed
    Score: 0.736
  3. New "21st Century Cures" Legislation: Speed and Ease vs Science. JAMA. 2017 02 14; 317(6):581-582.
    View in: PubMed
    Score: 0.728
  4. Six-Month Market Exclusivity Extensions To Promote Research Offer Substantial Returns For Many Drug Makers. Health Aff (Millwood). 2017 02 01; 36(2):362-370.
    View in: PubMed
    Score: 0.724
  5. Approving a Problematic Muscular Dystrophy Drug: Implications for FDA Policy. JAMA. 2016 12 13; 316(22):2357-2358.
    View in: PubMed
    Score: 0.719
  6. The 21st Century Cures Act. N Engl J Med. 2015 10 22; 373(17):1679-80.
    View in: PubMed
    Score: 0.665
  7. Forbidden and Permitted Statements about Medications--Loosening the Rules. N Engl J Med. 2015 Sep 03; 373(10):967-73.
    View in: PubMed
    Score: 0.658
  8. Erratum to: Methodological Approaches to Evaluate the Impact of FDA Drug Safety Communications. Drug Saf. 2015 Sep; 38(9):845.
    View in: PubMed
    Score: 0.658
  9. The 21st Century Cures Act--Will It Take Us Back in Time? N Engl J Med. 2015 Jun 25; 372(26):2473-5.
    View in: PubMed
    Score: 0.647
  10. Methodological approaches to evaluate the impact of FDA drug safety communications. Drug Saf. 2015 Jun; 38(6):565-75.
    View in: PubMed
    Score: 0.647
  11. Mandatory disclaimers on dietary supplements do not reliably communicate the intended issues. Health Aff (Millwood). 2015 Mar; 34(3):438-46.
    View in: PubMed
    Score: 0.636
  12. The roles of academia, rare diseases, and repurposing in the development of the most transformative drugs. Health Aff (Millwood). 2015 Feb; 34(2):286-93.
    View in: PubMed
    Score: 0.632
  13. Burden of changes in generic pill appearance. Ann Intern Med. 2014 Dec 02; 161(11):840.
    View in: PubMed
    Score: 0.625
  14. Existing FDA pathways have potential to ensure early access to, and appropriate use of, specialty drugs. Health Aff (Millwood). 2014 Oct; 33(10):1770-8.
    View in: PubMed
    Score: 0.618
  15. Clinicians' contributions to the development of coronary artery stents: a qualitative study of transformative device innovation. PLoS One. 2014; 9(2):e88664.
    View in: PubMed
    Score: 0.591
  16. New and unproved medical devices. BMJ. 2013 Dec 19; 347:f7413.
    View in: PubMed
    Score: 0.585
  17. Who is now responsible for discovering and warning about adverse effects of generic drugs? JAMA. 2013 Sep 11; 310(10):1023-4.
    View in: PubMed
    Score: 0.574
  18. Defining "innovativeness" in drug development: a systematic review. Clin Pharmacol Ther. 2013 Sep; 94(3):336-48.
    View in: PubMed
    Score: 0.563
  19. The most transformative drugs of the past 25 years: a survey of physicians. Nat Rev Drug Discov. 2013 06; 12(6):425-31.
    View in: PubMed
    Score: 0.562
  20. FDA regulation of off-label drug promotion under attack. JAMA. 2013 Feb 06; 309(5):445-6.
    View in: PubMed
    Score: 0.551
  21. Drug labels: a flawed source of data for studying orphan drug approvals. Clin Pharmacol Ther. 2012 Dec; 92(6):694; author reply 695.
    View in: PubMed
    Score: 0.539
  22. The Food and Drug Administration has the legal basis to restrict promotion of flawed comparative effectiveness research. Health Aff (Millwood). 2012 Oct; 31(10):2200-5.
    View in: PubMed
    Score: 0.538
  23. A randomized study of how physicians interpret research funding disclosures. N Engl J Med. 2012 Sep 20; 367(12):1119-27.
    View in: PubMed
    Score: 0.537
  24. Conflict of interest reporting by authors involved in promotion of off-label drug use: an analysis of journal disclosures. PLoS Med. 2012; 9(8):e1001280.
    View in: PubMed
    Score: 0.532
  25. The prevalence and cost of unapproved uses of top-selling orphan drugs. PLoS One. 2012; 7(2):e31894.
    View in: PubMed
    Score: 0.515
  26. False Claims Act prosecution did not deter off-label drug use in the case of neurontin. Health Aff (Millwood). 2011 Dec; 30(12):2318-27.
    View in: PubMed
    Score: 0.508
  27. The NIH translational research center might trade public risk for private reward. Nat Med. 2011 Oct 11; 17(10):1176.
    View in: PubMed
    Score: 0.503
  28. Characteristics of clinical trials to support approval of orphan vs nonorphan drugs for cancer. JAMA. 2011 Jun 08; 305(22):2320-6.
    View in: PubMed
    Score: 0.491
  29. A hemorrhage of off-label use. Ann Intern Med. 2011 Apr 19; 154(8):566-7.
    View in: PubMed
    Score: 0.486
  30. Using patent data to assess the value of pharmaceutical innovation. J Law Med Ethics. 2009; 37(2):176-83.
    View in: PubMed
    Score: 0.415
  31. Pharmaceutical promotion to physicians and First Amendment rights. N Engl J Med. 2008 Apr 17; 358(16):1727-32.
    View in: PubMed
    Score: 0.395
  32. Potential Medicare Savings From Generic Substitution and Therapeutic Interchange of ACE Inhibitors and Angiotensin-II-Receptor Blockers. JAMA Intern Med. 2019 12 01; 179(12):1712-1714.
    View in: PubMed
    Score: 0.221
  33. Multimodal Analysis of FDA Drug Safety Communications: Lessons from Zolpidem. Drug Saf. 2019 11; 42(11):1287-1295.
    View in: PubMed
    Score: 0.220
  34. The FDA Amendments Act of 2007 - Assessing Its Effects a Decade Later. N Engl J Med. 2018 Sep 20; 379(12):1097-1099.
    View in: PubMed
    Score: 0.203
  35. Medicare Spending on Brand-name Combination Medications vs Their Generic Constituents. JAMA. 2018 08 21; 320(7):650-656.
    View in: PubMed
    Score: 0.202
  36. An Incomplete Prescription: President Trump's Plan to Address High Drug Prices. JAMA. 2018 06 19; 319(23):2373-2374.
    View in: PubMed
    Score: 0.200
  37. Application and Impact of Run-In Studies for the Evaluation of Statin Efficacy and Safety. J Gen Intern Med. 2018 06; 33(6):792-794.
    View in: PubMed
    Score: 0.199
  38. The FDA Breakthrough-Drug Designation - Four Years of Experience. N Engl J Med. 2018 04 12; 378(15):1444-1453.
    View in: PubMed
    Score: 0.197
  39. Application and impact of run-in studies. J Gen Intern Med. 2018 05; 33(5):759-763.
    View in: PubMed
    Score: 0.195
  40. Adaptive design clinical trials: a review of the literature and ClinicalTrials.gov. BMJ Open. 2018 02 10; 8(2):e018320.
    View in: PubMed
    Score: 0.195
  41. Social Media Impact of the Food and Drug Administration's Drug Safety Communication Messaging About Zolpidem: Mixed-Methods Analysis. JMIR Public Health Surveill. 2018 Jan 05; 4(1):e1.
    View in: PubMed
    Score: 0.194
  42. Speed, Safety, and Industry Funding - From PDUFA I to PDUFA VI. N Engl J Med. 2017 12 07; 377(23):2278-2286.
    View in: PubMed
    Score: 0.193
  43. The Price of Crossing the Border for Medications. N Engl J Med. 2017 10 26; 377(17):1699-1700.
    View in: PubMed
    Score: 0.191
  44. The Price of Crossing the Border for Medications. N Engl J Med. 2017 Jul 27; 377(4):311-313.
    View in: PubMed
    Score: 0.188
  45. Success, Failure, and Transparency in Biomarker-Based Drug Development: A Case Study of Cholesteryl Ester Transfer Protein Inhibitors. Circ Cardiovasc Qual Outcomes. 2017 Jun; 10(6).
    View in: PubMed
    Score: 0.186
  46. Patient and Physician Perceptions of Drug Safety Information for Sleep Aids: A Qualitative Study. Drug Saf. 2017 06; 40(6):531-542.
    View in: PubMed
    Score: 0.186
  47. The Failure of Solanezumab - How the FDA Saved Taxpayers Billions. N Engl J Med. 2017 May 04; 376(18):1706-1708.
    View in: PubMed
    Score: 0.185
  48. Medicaid Expenditures and Estimated Rebates for Epinephrine Autoinjectors, 2012 to 2016. JAMA Intern Med. 2017 05 01; 177(5):734-736.
    View in: PubMed
    Score: 0.185
  49. Changes in prescribing and healthcare resource utilization after FDA Drug Safety Communications involving zolpidem-containing medications. Pharmacoepidemiol Drug Saf. 2017 Jun; 26(6):712-721.
    View in: PubMed
    Score: 0.185
  50. Applying Academic Detailing and Process Change to Promote Choosing Wisely. JAMA Intern Med. 2017 02 01; 177(2):282.
    View in: PubMed
    Score: 0.182
  51. Factors Influencing Prescription Drug Costs in the United States-Reply. JAMA. 2016 12 13; 316(22):2431-2432.
    View in: PubMed
    Score: 0.180
  52. Comparative effectiveness and safety of thalidomide and lenalidomide in patients with multiple myeloma in the United States of America: A population-based cohort study. Eur J Cancer. 2017 01; 70:22-33.
    View in: PubMed
    Score: 0.179
  53. Physicians' Trust in the FDA's Use of Product-Specific Pathways for Generic Drug Approval. PLoS One. 2016; 11(10):e0163339.
    View in: PubMed
    Score: 0.178
  54. Effect of Generic Competition on Atorvastatin Prescribing and Patients' Out-of-Pocket Spending. JAMA Intern Med. 2016 09 01; 176(9):1317-23.
    View in: PubMed
    Score: 0.176
  55. The High Cost of Prescription Drugs in the United States: Origins and Prospects for Reform. JAMA. 2016 Aug 23-30; 316(8):858-71.
    View in: PubMed
    Score: 0.175
  56. State Initiatives to Control Medication Costs--Can Transparency Legislation Help? N Engl J Med. 2016 Jun 16; 374(24):2301-4.
    View in: PubMed
    Score: 0.174
  57. Association of Industry Payments to Physicians With the Prescribing of Brand-name Statins in Massachusetts. JAMA Intern Med. 2016 06 01; 176(6):763-8.
    View in: PubMed
    Score: 0.173
  58. Inaccurate Reporting of Insulin Reimbursement-Reply. JAMA Intern Med. 2016 Mar; 176(3):408-9.
    View in: PubMed
    Score: 0.170
  59. Variations in Patients' Perceptions and Use of Generic Drugs: Results of a National Survey. J Gen Intern Med. 2016 06; 31(6):609-14.
    View in: PubMed
    Score: 0.170
  60. Do March-In Rights Ensure Access to Medical Products Arising From Federally Funded Research? A Qualitative Study. Milbank Q. 2015 Dec; 93(4):761-87.
    View in: PubMed
    Score: 0.167
  61. Medical Schools' Industry Interaction Policies Not Associated With Trainees' Self-Reported Behavior as Residents: Results of a National Survey. J Grad Med Educ. 2015 Dec; 7(4):595-602.
    View in: PubMed
    Score: 0.167
  62. Trends in Medicaid Reimbursements for Insulin From 1991 Through 2014. JAMA Intern Med. 2015 Oct; 175(10):1681-6.
    View in: PubMed
    Score: 0.165
  63. Progress and Hurdles for Follow-on Biologics. N Engl J Med. 2015 Jun 18; 372(25):2380-2.
    View in: PubMed
    Score: 0.161
  64. Paying physicians to prescribe generic drugs and follow-on biologics in the United States. PLoS Med. 2015 Mar; 12(3):e1001802.
    View in: PubMed
    Score: 0.159
  65. Practical, legal, and ethical issues in expanded access to investigational drugs. N Engl J Med. 2015 Jan 15; 372(3):279-86.
    View in: PubMed
    Score: 0.158
  66. Are risk evaluation and mitigation strategies associated with less off-label use of medications? The case of immune thrombocytopenia. Clin Pharmacol Ther. 2015 Feb; 97(2):186-93.
    View in: PubMed
    Score: 0.157
  67. Association of medical students' reports of interactions with the pharmaceutical and medical device industries and medical school policies and characteristics: a cross-sectional study. PLoS Med. 2014 Oct; 11(10):e1001743.
    View in: PubMed
    Score: 0.155
  68. Electronic medication packaging devices and medication adherence: a systematic review. JAMA. 2014 Sep 24; 312(12):1237-47.
    View in: PubMed
    Score: 0.154
  69. Association of marketing interactions with medical trainees' knowledge about evidence-based prescribing: results from a national survey. JAMA Intern Med. 2014 Aug; 174(8):1283-90.
    View in: PubMed
    Score: 0.153
  70. Burden of changes in pill appearance for patients receiving generic cardiovascular medications after myocardial infarction: cohort and nested case-control studies. Ann Intern Med. 2014 Jul 15; 161(2):96-103.
    View in: PubMed
    Score: 0.152
  71. New FDA breakthrough-drug category--implications for patients. N Engl J Med. 2014 07 03; 371(1):89-90.
    View in: PubMed
    Score: 0.152
  72. Restrictions on pharmaceutical detailing reduced off-label prescribing of antidepressants and antipsychotics in children. Health Aff (Millwood). 2014 Jun; 33(6):1014-23.
    View in: PubMed
    Score: 0.151
  73. Life cycle of medical product rules issued by the US Food and Drug Administration. J Health Polit Policy Law. 2014 Aug; 39(4):751-80.
    View in: PubMed
    Score: 0.151
  74. Using a drug-safety tool to prevent competition. N Engl J Med. 2014 Apr 17; 370(16):1476-8.
    View in: PubMed
    Score: 0.150
  75. New FDA breakthrough-drug category--implications for patients. N Engl J Med. 2014 Mar 27; 370(13):1252-8.
    View in: PubMed
    Score: 0.149
  76. What is the public's right to access medical discoveries based on federally funded research? JAMA. 2014 Mar 05; 311(9):907-8.
    View in: PubMed
    Score: 0.148
  77. Quantifying The Food And Drug Administration's rulemaking delays highlights the need for transparency. Health Aff (Millwood). 2014 Feb; 33(2):309-15.
    View in: PubMed
    Score: 0.147
  78. Physician trainees' interactions with the pharmaceutical industry. J Gen Intern Med. 2013 Oct; 28(10):1267.
    View in: PubMed
    Score: 0.144
  79. Clinical and regulatory features of drugs not initially approved by the FDA. Clin Pharmacol Ther. 2013 Dec; 94(6):670-7.
    View in: PubMed
    Score: 0.143
  80. Changing interactions between physician trainees and the pharmaceutical industry: a national survey. J Gen Intern Med. 2013 Aug; 28(8):1064-71.
    View in: PubMed
    Score: 0.142
  81. Speaking the same language? International variations in the safety information accompanying top-selling prescription drugs. BMJ Qual Saf. 2013 Sep; 22(9):727-34.
    View in: PubMed
    Score: 0.140
  82. Variations in pill appearance of antiepileptic drugs and the risk of nonadherence. JAMA Intern Med. 2013 Feb 11; 173(3):202-8.
    View in: PubMed
    Score: 0.138
  83. Risk, responsibility, and generic drugs. N Engl J Med. 2012 11 01; 367(18):1679-81.
    View in: PubMed
    Score: 0.135
  84. Origins of medical innovation: the case of coronary artery stents. Circ Cardiovasc Qual Outcomes. 2012 Nov; 5(6):743-9.
    View in: PubMed
    Score: 0.135
  85. Conflict of interest in oncology publications: a survey of disclosure policies and statements. Cancer. 2012 Jan 01; 118(1):188-95.
    View in: PubMed
    Score: 0.123
  86. Medical students' exposure to and attitudes about the pharmaceutical industry: a systematic review. PLoS Med. 2011 May; 8(5):e1001037.
    View in: PubMed
    Score: 0.122
  87. Designing comparative effectiveness research on prescription drugs: lessons from the clinical trial literature. Health Aff (Millwood). 2010 Oct; 29(10):1842-8.
    View in: PubMed
    Score: 0.117
  88. Seizure outcomes following the use of generic versus brand-name antiepileptic drugs: a systematic review and meta-analysis. Drugs. 2010 Mar 26; 70(5):605-21.
    View in: PubMed
    Score: 0.113
  89. Balancing innovation, access, and profits--market exclusivity for biologics. N Engl J Med. 2009 Nov 12; 361(20):1917-9.
    View in: PubMed
    Score: 0.109
  90. Use of Health Care Databases to Support Supplemental Indications of Approved Medications. JAMA Intern Med. 2018 01 01; 178(1):55-63.
    View in: PubMed
    Score: 0.048
  91. Strategies That Delay Market Entry of Generic Drugs. JAMA Intern Med. 2017 11 01; 177(11):1665-1669.
    View in: PubMed
    Score: 0.048
  92. Comparative effectiveness of generic versus brand-name antiepileptic medications. Epilepsy Behav. 2015 Nov; 52(Pt A):14-8.
    View in: PubMed
    Score: 0.041
  93. Comparative effectiveness of generic and brand-name statins on patient outcomes: a cohort study. Ann Intern Med. 2014 Sep 16; 161(6):400-7.
    View in: PubMed
    Score: 0.038
  94. The consequences of requesting "dispense as written". Am J Med. 2011 Apr; 124(4):309-17.
    View in: PubMed
    Score: 0.030
  95. The variability and quality of medication container labels. Arch Intern Med. 2007 Sep 10; 167(16):1760-5.
    View in: PubMed
    Score: 0.024
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.